AYTU BIOPHARMA, INC Income Tax Expense (Benefit), Intraperiod Tax Allocation
AYTU BIOPHARMA, INC (AYTU) reported Income Tax Expense (Benefit), Intraperiod Tax Allocation of $21.00 thousand for the 12-month period ending 2026-06-30, per its 10-K filed 2026-09-22.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxExpenseBenefitIntraperiodTaxAllocation · last filed 2026-09-22
- AYTU BIOPHARMA, INC income tax expense (benefit), intraperiod tax allocation for fiscal 2026 was $21.00K, a 95.00% decline from fiscal 2025.
- AYTU BIOPHARMA, INC income tax expense (benefit), intraperiod tax allocation for fiscal 2025 was $420.00K, a 76.24% decline from fiscal 2024.
- AYTU BIOPHARMA, INC income tax expense (benefit), intraperiod tax allocation for fiscal 2024 was $1.77M.
| Period end | Income Tax Expense (Benefit), Intraperiod Tax Allocation 12 month |
|---|---|
| 2026-06-30 | $21.00K 10-K · filed 2026-09-22 |
| 2025-06-30 | $420.00K 10-K · filed 2026-09-22 |
| 2024-06-30 | $1.77M 10-K · filed 2025-09-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |
| ARTELO BIOSCIENCES, INC. (ARTL) | United States | $0.023B | |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |